Simple Summary Circulating tumor DNA is DNA released by the tumor into the bloodstream.
In breast cancer, it is used mainly in research or in clinical trials, but it will likely be used in …

Simple Summary Breast cancer is the most common cancer and leading cause of death
worldwide. Therefore, it is important to diagnose and treat breast cancer early. Current …

Background Triple negative breast cancer (TNBC) is an aggressive subtype with poor
prognosis. We aimed to determine whether circulating tumor DNA (ctDNA) and circulating …

Triple-negative breast cancer is a sub-type of clinically and molecularly heterogeneous
malignant disease with a worse prognosis and earlier recurrence than HER2-amplified or …

Background N6-methyladenosine (m6A) is most common internal RNA modification in
eukaryotic cells. Existing evidence shows that m6A is closely related to pathogenesis and …

Breast cancer is the most common cancer among women in the world as well as in the
United States. Molecular and histological differentiation have helped clinicians optimize …

Approximately 6% of metastatic breast cancers arise de novo. While systemic therapy (ST)
remains the treatment backbone as for patients with metachronous metastases, locoregional …

Simple Summary Circular RNAs (circRNAs) consist of covalently closed structures without a
free 3′ poly (A) tail or 5′ cap. Due to their loop structures, circRNAs are largely stable and …

Breast cancer (BC) is one of the most significant neoplasms globally due to its high
incidence and mortality, particularly among females. As a highly heterogeneous pathology …

The detection of circulating tumor DNA (ctDNA) in the plasma of cancer patients is emerging
as a very sensitive and specific prognostic biomarker. Previous studies with ctDNA have …